15 Mar 2013 07:00
Press Release | 15 March 2013 |
LiDCO Group Plc
("LiDCO" or the "Company")
Grant of LiDCOrapid GUI patent in Japan
LiDCO Group Plc (AIM:LID), the cardiovascular monitoring company, announces that the Japan Patent Office has granted a patent protecting the novel Graphical User Interface ("GUI") of the LiDCOrapid monitor in Japan, the world's second largest market for hemodynamic monitoring.
The distinctive display of hemodynamic parameters by LiDCO's GUI makes the touch-screen monitor unique and more interpretable than traditional displays in the surgical setting. This GUI forms the structure of the screen displayed by the new LiDCOrapid v2 with Unity software. A patent protecting the GUI was granted in the EU in September 2011 and is currently pending in the US.
Japan is one of LiDCO's most significant markets, along with the UK and US. The LiDCOrapid has been available for sale in Japan since June 2012. The LiDCOrapid and disposable Smartcards are distributed for LiDCO throughout Japan by Nihon Kohden, a pioneer and global market leader in monitoring technology.
Terry O'Brien, Chief Executive Officer of LiDCO, commented: "The grant of a patent covering our user interface in the EU and now Japan is extremely significant for LiDCO. We estimate the Japanese minimally invasive hemodynamic monitoring market to be worth US$285 million per annum, making it LiDCO's second largest market. This straightforward user interface gives our monitor a unique and important competitive edge over other technologies and has been recognised as being both novel and protectable."
- ENDS -
For further information, please contact:
LiDCO Group Plc | |
Theresa Wallis (Chairman) | Tel: +44 (0)20 7749 1500 |
Paul Clifford (Finance Director) | |
John Rowland (Company Secretary) | www.lidco.com |
FinnCap | |
Geoff Nash / Henrik Persson Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
Abchurch | |
Adam Michael / Simone Elviss / Jamie Hooper | Tel: +44 (0) 20 7398 7719 |
Jamie.hooper@abchurch-group.com | www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
Key Products:
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%) | |
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides: | |
·; | early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug |
·; | quantification of hemodynamic response, |
·; | guidance on effective delivery of fluids to ensure the right amount at the right time |
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data. | |
LiDCO Unity Software: The software incorporated into LiDCOrapid v2 will allow the LiDCOrapid monitor to co-display Covidien's level of consciousness parameter and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring. This will address a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors. | |
All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.
LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.